Unknown

Dataset Information

0

Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer.


ABSTRACT: Neoadjuvant chemotherapy (NACT) has been established as being an effective treatment for advanced gastric cancer (GC), while the predictive biomarker of NACT efficacy remains under investigation. Aspartate β-hydroxylase (ASPH) represents an attractive target which is a highly conserved transmembrane enzyme overexpressed in human GC, and participates in the malignant transformation by promoting tumor cell motility. Here, we evaluated the expression of ASPH by immunohistochemistry in 350 GC tissues (including samples for NACT) and found that ASPH expression was higher in patients undergoing NACT compared with patients without NACT pre-operation. The OS and PFS time of ASPH-intensely positive patients was significantly shorter than that of the negative patients in the NACT group, while the difference was not significant in patients without NACT. We showed that ASPH knockout enhanced the inhibitory effects of chemotherapeutic drugs on the cell proliferation, migration, and invasion in vitro and suppressed tumor progression in vivo. Co-immunoprecipitation revealed that ASPH might interact with LAPTM4B to perform chemotherapeutic drug resistance. Our results suggested that ASPH might serve as a candidate biomarker to predict prognosis and a novel therapeutic target for gastric cancer patients treated with neoadjuvant chemotherapy.

SUBMITTER: Gan X 

PROVIDER: S-EPMC10053938 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer.

Gan Xuejun X   Li Shen S   Wang Yiding Y   Du Hong H   Hu Ying Y   Xing Xiaofang X   Cheng Xiaojing X   Yan Yan Y   Li Ziyu Z  

International journal of molecular sciences 20230313 6


Neoadjuvant chemotherapy (NACT) has been established as being an effective treatment for advanced gastric cancer (GC), while the predictive biomarker of NACT efficacy remains under investigation. Aspartate β-hydroxylase (ASPH) represents an attractive target which is a highly conserved transmembrane enzyme overexpressed in <i>human</i> GC, and participates in the malignant transformation by promoting tumor cell motility. Here, we evaluated the expression of ASPH by immunohistochemistry in 350 GC  ...[more]

Similar Datasets

| S-EPMC8593195 | biostudies-literature
| S-EPMC8947299 | biostudies-literature
| S-EPMC9250877 | biostudies-literature
| S-EPMC7433162 | biostudies-literature
| S-EPMC11919673 | biostudies-literature
| S-EPMC7601042 | biostudies-literature
| S-EPMC8414610 | biostudies-literature
| S-EPMC10331735 | biostudies-literature
| S-EPMC2992682 | biostudies-other
| S-EPMC7070044 | biostudies-literature